The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1644
ISSUE1644
February 21, 2022
Remimazolam (Byfavo) for Short-Term Procedural Sedation
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Remimazolam (Byfavo) for Short-Term Procedural Sedation
February 21, 2022 (Issue: 1644)
The FDA has approved remimazolam (Byfavo – Acacia
Pharma), an ultra-short-acting IV benzodiazepine,
for induction and maintenance of sedation in adults
undergoing procedures of up to 30 minutes' duration.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.